Key result
Prasugrel and ticagrelor cut MACE up to ~20% vs. placebo in CAD with diabetes.
Why the study?
Patients with DM and CAD are at high risk of thrombotic events and have reduced responsiveness to conventional antiplatelet therapy, leaving the optimal P2Y12 inhibitor strategy uncertain.
Do P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) reduce major adverse cardiovascular events in patients with diabetes mellitus and coronary artery disease?
Meta-Analysis (n=40,919)
Do P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) reduce major adverse cardiovascular events in patients with diabetes mellitus and coronary artery disease?
In patients with diabetes and coronary artery disease, prasugrel and ticagrelor offer superior ischemic protection compared to clopidogrel, but at the cost of increased bleeding risk.
Supports prasugrel or ticagrelor over clopidogrel for MACE reduction in diabetic CAD on aspirin; extends RCT network evidence with placebo comparisons.
Background: Patients with diabetes mellitus (DM) and coronary artery disease (CAD) are at high risk of thrombotic events and exhibit reduced responsiveness to conventional antiplatelet therapy. While newer P2Y12 inhibitors such as ticagrelor and prasugrel provide more potent platelet inhibition, the optimal therapeutic strategy in this population remains uncertain. Methods: A systematic review and network meta-analysis of randomized controlled trials (RCTs) was conducted in accordance with PRISMA guidelines. Electronic databases were searched through April 2026 to identify RCTs comparing clopidogrel, prasugrel, ticagrelor, and placebo in patients with DM and CAD receiving background aspirin therapy. Random-effects models were used to estimate pooled risk ratios (RRs) with 95% confidence intervals (CIs). The primary efficacy outcome was major adverse cardiovascular events (MACEs), while safety outcomes included major bleeding. Results: Seventeen RCTs, including 40,919 patients, were identified, with 15 trials included in the quantitative synthesis. Compared with placebo, prasugrel and ticagrelor were associated with significant reductions in MACEs, whereas clopidogrel showed no significant benefit. No significant differences were observed in cardiovascular or all-cause mortality across treatment strategies. Prasugrel was associated with a lower risk of myocardial infarction, while ticagrelor was associated with a lower risk of stroke. Both agents increased major bleeding versus placebo, and ticagrelor was also associated with a higher risk of dyspnea. Ranking analysis suggested that prasugrel was the most effective strategy for ischemic outcomes, whereas placebo was the safest strategy overall. Conclusions: In patients with DM and CAD, prasugrel and ticagrelor provide superior protection against ischemic events compared with clopidogrel but are associated with an increased bleeding risk compared with placebo. Prasugrel appears to offer the greatest overall efficacy, while ticagrelor shows a distinct benefit in stroke prevention. These findings support individualized antiplatelet strategies that balance ischemic and bleeding risks in this high-risk population.
No takes yet. Share an insight, caveat, or question.
Aljohani et al. (2026) conducted a meta-analysis in Diabetes Mellitus and Coronary Artery Disease (n=40,919). Prasugrel vs. Placebo was evaluated on Major adverse cardiovascular events (MACEs) (RR 0.80, 95% CI 0.67-0.95). Prasugrel and ticagrelor significantly reduced major adverse cardiovascular events compared to placebo (RR 0.80 and 0.89, respectively) in patients with diabetes and coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: